Serbian opposition lawmakers threw smoke grenades and tear gas inside parliament on Tuesday to protest against the government ...

The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.

Research predicts stroke deaths may rise 50% globally by 2050, with younger people increasingly affected. Learn effective ...

Discover how hypertension, diabetes, atrial fibrillation, high cholesterol, and obesity increase stroke risk, and learn ...

Researchers at Karolinska Institutet have identified a new mechanism that may improve the treatment of ischemic stroke. The ...

Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the standard 60-minute infusion of alteplase.

The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according ...

According to Roche subsidiary Genentech, which announced the label expansion on Monday, TNKase is the first new drug for ...

Students part of Project WeCan’s ‘Becoming a Writer’ course talk to the project director to learn about innovations at the ...

Women with one or more gynecological disorders had higher risk of heart disease and clogged arteries affecting either their ...